CD8A and neoplasm: Evidence suggests that the TIGIT blocking may restore T cell activity in cancer patients and that dual blockade of TIGIT and PD-1/PD-L1 improving synergistically the CD8+ T cells antitumor function in mice, results in an increased protective activity of memory T cells, in a complete tumor rejection, and a prolonged OS [104].